HY-004 provides a new treatment alternative for use in patients on anti-coagulant therapies undergoing dental procedures that have a risk of bleeding or complication HY-004 administered locally had ...
Hyloris Reports Positive Phase 1 Data for HY-004, a proprietary Tranexamic Acid Oral Mouth Rinse for bleeding related to dental procedures HY-004 provides a new treatment alternative for use in ...
Hyloris Pharmaceuticals SA, a specialty biopharma company, announced positive results from a phase 1 study of HY-004, an antifibrinolytic agent, tranexamic acid, as an oral mouth rinse proprietary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback